What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid (5-ALA) for Fluorescence-Guided Surgery of Brain Tumors?

Faculty:
 
Costas G. Hadjipanayis, MD, PhD, FAANS

Professor and Chair
Dept. of Neurosurgery, Mount Sinai Beth Israel

Director, Neurosurgical Oncology
Mount Sinai Health System
Icahn School of Medicine at Mount Sinai

Director, Brain Tumor Nanotechnology Laboratory
Tisch Cancer Institute
 

Course Description:
 
This webinar will examine the surgical benefit of using 5-ALA for fluorescence-guided surgery (FGS) of brain tumors. The participants will be introduced to the concept of FGS and understand how 5-ALA can help neurosurgeons identify in real-time tumor tissue for resection purposes. As part of this webinar, 5-ALA in different tumor types will be discussed mainly focusing on malignant gliomas. The safety aspects of 5-ALA administration will be discussed in addition to the current state of regulatory approval for use in the United States.


Learning Objectives:
 
Upon completion of this activity, participants should be able to:
 
-Identify 5-ALA and its intracellular fluorescent metabolite, protoporphyrin IX in brain tumors.

-Discuss the technical aspects of 5-ALA fluorescence-guided surgery including the use of 5-ALA FGS for real-time intraoperative guidance, tumor margin visualization, and reported extents of resection.

-Review patient safety and the current state of regulatory approval of 5-ALA.

-Recognize the surgical benefits of 5-ALA for fluorescence-guided surgery.
 
 
***This webinar does not provide CME credit.
 

Costas G. Hadjipanayis

MD, PhD, FAANS

Professor and Chair
Dept. of Neurosurgery, Mount Sinai Beth Israel


Director, Neurosurgical Oncology
Mount Sinai Health System
Icahn School of Medicine at Mount Sinai


Director, Brain Tumor Nanotechnology Laboratory
Tisch Cancer Institute

How did you hear about this Webinar?


Please login to access this poll.
Components visible upon registration.